The breakthrough medicines program is a transformative designation for novel solutions addressing critical medical needs. The Saudi Food and Drug Authority (SFDA) recognizes the significance of these groundbreaking therapies. It established this particular designation as a perk for new drug registration applications (NDAs) to facilitate their development and expedite their approval.

In this post, we delve into the critical aspects of the SFDA’s approach to breakthrough medicines.

Defining Breakthrough Medicines

Breakthrough medicines represent a paradigm shift in the treatment landscape, offering substantial advantages over existing therapies for severe or life-threatening conditions. These medicines demonstrate significant improvements in efficacy or safety compared with available treatments, potentially altering the course of patient care.

This program is voluntary, and the request can be made by the end of phase 2 or at any time afterward; the decision is based on whether the benefits outweigh the risks.

The SFDA’s commitment to advancing public health is evident in its proactive stance towards breakthrough medicines. By recognizing the unique challenges and opportunities associated with these transformative therapies, the SFDA aims to streamline its development and regulatory approval processes.

Criteria for Breakthrough Designation

To qualify for the breakthrough designation, a drug must meet specific criteria outlined by the SFDA below:

Target serious, debilitating, or life-threatening conditions with unmet medical needs.
The medicinal product is likely to offer a significant advantage over current methods.
The benefits outweigh the potential adverse effects of the medicinal product, supporting a reasonable expectation of a positive benefit/risk balance.
The product is not registered with any regulatory authority at the time of its submission.

Note that advanced therapies, such as cell & gene therapies, are always candidates for this designation in Saudi Arabia.

Collaborative Development Plans

The SFDA encourages open communication and collaboration between drug developers and regulatory authorities. This collaborative approach involves creating development plans that outline key milestones and ensure transparency and alignment among all stakeholders.

Regulatory Requirements and Timelines

The SFDA exercises flexibility in regulatory requirements for breakthrough medicines while maintaining a robust scientific evaluation. If any of the registration requirements (e.g., CPP, leaflet, and artwork) are unavailable, the applicant may request an exemption.

The applicant must submit the application file within 30 working days of the designation being granted through the Saudi Drug Registration (SDR) System.

The scientific committee normally reviews the application within 30 working days of the receipt of the request. It mainly focuses on the potential of the medicinal products and the data formats. While scientific assessment may take approx. 60 working days in case complete data is provided in the application.

In case of inquiries, the applicant may submit its response within 60 working days, which can be extended depending upon the circumstances.

In case of incomplete data, SFDA may provide scientific advice either regarding the design and conduct of drug development or regarding the conduct of a clinical trial.

Schematic overview of Breakthrough Medicines Program

Post-Market Monitoring

Even after regulatory approval, the SFDA continues to monitor breakthrough medicines post-market actively. This ongoing surveillance ensures the ongoing safety and efficacy of these therapies and promptly addresses any emerging concerns.

However, the Breakthrough Medicine Designation may be withdrawn if emerging data indicate that it no longer meets the required criteria.

Impact on Patient Care

The SFDA’s commitment to breakthrough medicines profoundly impacts patient care in Saudi Arabia. By expediting the development and approval of transformative therapies, the SFDA helps ensure the availability of cutting-edge treatments, offering new hope to patients with severe or life-threatening conditions.

Conclusion

In embracing the era of breakthrough medicines, the SFDA positions itself as a facilitator of innovation and a guardian of public health. The guidelines for breakthrough designation not only encourage the development of transformative therapies but also exemplify the SFDA’s dedication to ensuring that these advancements reach patients promptly and responsibly.

As the landscape of medical innovation continues to evolve, the SFDA’s commitment to breakthrough medicines remains steadfast. It promises a future in which groundbreaking therapies become more accessible.

If you are applying for the Breakthrough designation program, let’s connect with our expert team to streamline your journey to acquire BMD from SFDA.